Irosustat monotherapy halt adds to Ipsen's litany of disappointment
This article was originally published in Scrip
Executive Summary
France's Ipsen is facing more pipeline woes with the news that it is discontinuing the development of its anticancer, Irosustat (BN 83495), as a monotherapy.